Connect to other sites within the UBM Medica Network
The sodium glucose cotransporter-2 inhibitors are the newest diabetes drugs available. Have you got the basic concepts under your belt? Try these 6 questions and find out.
Do SGLT2 Inhibitors Affect More Than Renal Cells?
We've been told that SGLT2 inhibitors only work on receptors in the kidneys, but a new study reveals a previously unknown function, as well as a new mechanism of action.
In Development in Diabetes: 4 Amazing Technologies
What’s around the corner? Take a peek at 4 technologies in progress aimed at improving diabetes management.
GLP-1: Used Only as Needed
The ADA recommends GLP-1 agonists as second-line therapy against type 2 diabetes. What makes this class unique in its impact on hyperglycemia?
Metabolic Disease Research Roundup From AACE 2015
Metabolic disorders in patients with diabetes place them at particularly high risk for CV morbidity. Find insights on Dx and Tx in these slides.
Incretin Therapy Side Effects Linked to Age, No Metformin Use
GI side effects compel many patients to stop GLP-1 agonist therapy. A new study identifies important risk factors to consider before prescribing.
GLP-1 Agonist Fails to Improve Coronary Flow Reserve in New Study
Incretin-based therapies have shown beneficial effects on the cardiovascular system, providing impetus for this recent study.
SGLT2 Inhibitors: Check Your A1c and BPs
Try this mid-week Q&A on 2 essential properties of the sodium glucose cotransporter 2 (SGLT2) inhibitors.
Top 10 Reasons Why Patients Come to Primary Care
What brings patients to your office—and not the specialty office down the street? Insights in this slideshow.
Abridged Diabetes Guidelines for Primary Care: 6 Noteworthy Changes
The ADA provides an abridged version for PCPs of its annual Standards of Medical Care. Our slides summarize 6 updates important to primary care.
Five Top Papers From 2014 That Will Impact Your Practice
New drugs that treat stubborn illness seen often in primary care lead this group of Top 5 Papers for 2014. Type 2 diabetes, cryptogenic stroke, and hep-C are key targets.
By clicking Accept, you agree to become a member of the UBM Medica Community.